BOSTON, June 27, 2023 (GLOBE NEWSWIRE) Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation,
Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
16.02.2023 - - Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial - - Rapid and significant increase in PPi observed in all dose cohorts .
- Article in Orphanet Journal of Rare Diseases estimates genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies, more than tripling prior estimate - - Company estimates addressable patient. | December 5, 2022